These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23847702)

  • 41. Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.
    Patel AK; Pujari S; Patel K; Patel J; Shah N; Patel B; Gupte N
    J Assoc Physicians India; 2006 Dec; 54():915-8. PubMed ID: 17334006
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
    Penazzato M; Giaquinto C
    Drugs; 2011 Nov; 71(16):2131-49. PubMed ID: 22035514
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lymphocyte mitochondrial depolarization and apoptosis in HIV-1-infected HAART patients.
    Karamchand L; Dawood H; Chuturgoon AA
    J Acquir Immune Defic Syndr; 2008 Aug; 48(4):381-8. PubMed ID: 18614930
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.
    van Leth F; Conway B; Laplumé H; Martin D; Fisher M; Jelaska A; Wit FW; Lange JM;
    Antivir Ther; 2004 Oct; 9(5):721-8. PubMed ID: 15535409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
    Jiang HY; Zhang MN; Chen HJ; Yang Y; Deng M; Ruan B
    Int J Infect Dis; 2014 Aug; 25():130-5. PubMed ID: 24911886
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
    Mankhatitham W; Lueangniyomkul A; Manosuthi W
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):651-8. PubMed ID: 21706943
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
    AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
    Cain LE; Phillips A; Lodi S; Sabin C; Bansi L; Justice A; Tate J; Logan R; Robins JM; Sterne JA; van Sighem A; de Wolf F; Bucher HC; Elzi L; Touloumi G; Vourli G; Esteve A; Casabona J; del Amo J; Moreno S; Seng R; Meyer L; Pérez-Hoyos S; Muga R; Abgrall S; Costagliola D; Hernán MA;
    AIDS; 2012 Aug; 26(13):1691-705. PubMed ID: 22546987
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
    Murnane PM; Strehlau R; Shiau S; Patel F; Mbete N; Hunt G; Abrams EJ; Coovadia A; Kuhn L
    Clin Infect Dis; 2017 Aug; 65(3):477-485. PubMed ID: 28419200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
    Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of non-nucleoside analogues together with rifampin in HIV patients with tuberculosis.
    Villar J; Sánchez P; González A; Sorli L; Montero MM; Guelar A; Solé E; López JL; Knobel H
    HIV Clin Trials; 2011; 12(3):171-4. PubMed ID: 21684857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
    Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
    PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire.
    Ekouevi DK; Coffie PA; Ouattara E; Moh R; Amani-Bosse C; Messou E; Sissoko M; Anglaret X; Eholié SP; Danel C; Dabis F; ;
    J Acquir Immune Defic Syndr; 2011 Feb; 56(2):183-7. PubMed ID: 21084995
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
    Manfredi R; Calza L; Chiodo F
    HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.
    Padmapriyadarsini C; Bhavani PK; Tang A; Kumar H; Ponnuraja C; Narendran G; Hannah E; Ramesh C; Chandrasekar C; Wanke C; Swaminathan S
    Int J Infect Dis; 2013 Dec; 17(12):e1154-9. PubMed ID: 24120216
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
    van Leth F; Andrews S; Grinsztejn B; Wilkins E; Lazanas MK; Lange JM; Montaner J;
    AIDS; 2005 Mar; 19(5):463-71. PubMed ID: 15764851
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.
    Antinori A; Zaccarelli M; Cingolani A; Forbici F; Rizzo MG; Trotta MP; Di Giambenedetto S; Narciso P; Ammassari A; Girardi E; De Luca A; Perno CF
    AIDS Res Hum Retroviruses; 2002 Aug; 18(12):835-8. PubMed ID: 12201905
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
    Torre D; Tambini R; Speranza F
    HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.